Memorial Sloan Kettering Cancer Center (US)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
184
Publications
1350
Citations
229656
i10-index
557
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
Improved Survival with Ipilimumab in Patients with... | 2010 | 16562 |
Combined Nivolumab and Ipilimumab or Monotherapy i... | 2015 | 8937 |
Mutational landscape determines sensitivity to PD-... | 2015 | 8604 |
Cancer immunotherapy using checkpoint blockade | 2018 | 7431 |
Overall Survival with Combined Nivolumab and Ipili... | 2017 | 5749 |
Ipilimumab plus Dacarbazine for Previously Untreat... | 2011 | 4909 |
Genetic Basis for Clinical Response to CTLA-4 Bloc... | 2014 | 4685 |
Nivolumab plus Ipilimumab in Advanced Melanoma | 2013 | 4553 |
Tumor mutational load predicts survival after immu... | 2019 | 4513 |
Five-Year Survival with Combined Nivolumab and Ipi... | 2019 | 4111 |
Jedd D. Wolchok is a researcher with 1350 publications and 229656 citations. They are affiliated with Memorial Sloan Kettering Cancer Center. Their research focuses on Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Cutaneous Melanoma Detection and Management and other areas. With an h-index of 184, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Jedd D. Wolchok and 300M+ other papers.
Citations per publication by year